Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value

1.8 / 5 stars · 42/120 Roast Me

GILEAD SCIENCES, INC. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value

GILEAD SCIENCES, INC. (GILD) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value of $12.83 billion as of 2017-09-30, per its 10-Q filed 2017-11-07.

Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue · last filed 2017-11-07

  • 2017-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value $12.83B.
  • 2017-06-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value $15.27B.
  • 2017-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value $19.23B.
  • 2016-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value $18.66B.
Period endDebt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value
2017-09-30$12.83B
10-Q · filed 2017-11-07
2017-06-30$15.27B
10-Q · filed 2017-08-07
2017-03-31$19.23B
10-Q · filed 2017-05-10
2016-09-30$18.66B
10-Q · filed 2016-11-07
2016-06-30$15.52B
10-Q · filed 2016-08-05
2016-03-31$12.79B
10-Q · filed 2016-05-06
2015-09-30$9.26B
10-Q · filed 2015-11-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31